DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.982
EU - Europa 4.330
AS - Asia 930
Continente sconosciuto - Info sul continente non disponibili 28
SA - Sud America 11
AF - Africa 6
OC - Oceania 5
Totale 14.292
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.729
PL - Polonia 1.674
IT - Italia 853
CN - Cina 802
DE - Germania 448
UA - Ucraina 331
GB - Regno Unito 280
CA - Canada 253
SE - Svezia 240
FR - Francia 194
FI - Finlandia 128
IE - Irlanda 84
VN - Vietnam 51
BE - Belgio 28
EU - Europa 27
KR - Corea 24
NL - Olanda 17
IN - India 16
RU - Federazione Russa 12
RO - Romania 10
BR - Brasile 7
SG - Singapore 7
TR - Turchia 7
HK - Hong Kong 6
AU - Australia 5
DK - Danimarca 5
AT - Austria 4
JP - Giappone 4
LB - Libano 4
BG - Bulgaria 3
RS - Serbia 3
CO - Colombia 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
JO - Giordania 2
LT - Lituania 2
NO - Norvegia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
CH - Svizzera 1
CM - Camerun 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
ES - Italia 1
ET - Etiopia 1
KE - Kenya 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 14.292
Salva come PNG Salva come JPEG
Città #
Warsaw 1.456
Fairfield 1.295
Woodbridge 971
Jacksonville 793
Ashburn 631
Houston 611
Chandler 567
Seattle 526
Wilmington 512
Ann Arbor 483
Cambridge 449
Nanjing 241
Kraków 213
Camerino 211
Toronto 192
San Mateo 117
Dearborn 111
Lawrence 111
Princeton 111
Boardman 93
Columbus 91
Ogden 89
London 83
Dublin 82
Beijing 80
Düsseldorf 74
San Diego 72
Nanchang 71
Lachine 57
Helsinki 54
Dong Ket 49
New York 48
Kunming 46
Milan 45
Tianjin 44
Shenyang 41
Hebei 36
Centro 34
Brussels 28
Philadelphia 24
Changsha 23
Jiaxing 23
Falls Church 22
Redwood City 22
Jinan 21
Hefei 20
Los Angeles 20
Norwalk 20
Scafati 20
Ningbo 19
Hangzhou 18
San Francisco 16
Shanghai 16
Verona 16
Zhengzhou 16
Venezia 15
Guangzhou 14
Bologna 13
Nürnberg 12
Ancona 11
Bremen 11
Council Bluffs 11
New Bedfont 11
Orange 11
Taizhou 11
Tappahannock 11
Hounslow 10
Caserta 9
Perugia 9
Meppel 8
Acton 7
Auburn Hills 7
Changchun 7
Chicago 7
Indiana 7
Kocaeli 7
Scuola 7
Seoul 7
Washington 7
Buffalo 6
Lanzhou 6
Old Bridge 6
Pawcatuck 6
Rome 6
Venice 6
Alessandria 5
Ascoli Piceno 5
Horia 5
Kilburn 5
Modena 5
Münster 5
San Germano Vercellese 5
Sindelfingen 5
Strasbourg 5
Varese 5
Frankfurt am Main 4
Leawood 4
Naples 4
Napoli 4
New Delhi 4
Totale 11.470
Salva come PNG Salva come JPEG
Nome #
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 320
Overview on Radiolabel-Free in Vitro Assays for GPCRs 308
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 268
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 261
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 259
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 253
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 242
The G Protein-Coupled Receptor GPR17: Overview and Update 240
Pharmacological characterization of the GPR17 receptor dual profile 236
Emerging Roles of Purinergic Signaling in Diabetes 236
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 234
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 208
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 203
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 201
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 198
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 196
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 196
P2X7 Receptor as a Therapeutic Target 189
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 186
GPR17 receptor modulators and their therapeutic implications: review of recent patents 181
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 173
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 169
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 169
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 167
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 163
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 162
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 156
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 156
Interaction model for anthracycline activity against DNA topoisomerase II 154
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 153
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 151
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 150
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 149
New sensible method to quantize the intestinal absorption of receptor ligands 149
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 147
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 147
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 144
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 144
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 143
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 143
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 142
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 141
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 141
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 141
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 140
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 139
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 139
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 137
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 137
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 136
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 135
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 134
null 134
The P2X7 Receptor in Infection and Inflammation 134
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 130
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 130
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 129
Antiviral properties of deazaadenine nucleoside derivatives 128
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 126
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 126
Adenosine receptor modeling: what does the A2A crystal structure tell us? 124
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 124
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 123
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 123
I protocolli operativi nella violenza di genere 123
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 122
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 120
Development of novel pyridazinone-based adenosine receptor ligands 116
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 115
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 110
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 106
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 101
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 101
Rational design of new competitive inhibitors of human CK2 activity 100
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 100
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 99
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 99
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 98
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 97
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 95
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 92
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 91
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 90
Letters in Drug Design & Discovery 90
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 87
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 83
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 81
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 78
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 78
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 77
Substituted adenine derivatives as novel P2X3 receptor ligands 76
New purine derivatives as P2X3 receptor antagonists 76
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 76
Mini-Reviews in Medicinal Chemistry 76
Identification of putative guanosine receptor in rat brain 75
Toward the rational design of Protein Kinase CK2 inhibitors 71
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 71
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 67
null 66
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A(1) adenosine receptor antagonists 65
Totale 14.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.326
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019673 0 0 0 0 0 0 0 0 0 0 320 353
2019/20203.390 368 155 320 663 198 271 245 309 232 202 153 274
2020/20213.472 163 267 181 286 213 450 666 100 299 222 369 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/2024865 161 64 80 49 57 114 65 92 138 44 1 0
Totale 14.684